Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Investigation of Pharmacokinetics, Safety, and Tolerability of a Single Oral 25 mg BAY 1142524 IR Tablet Dose in Male and Female Subjects With Renal Impairment and in Age-, Gender-, and Weight-matched Healthy Subjects in a Single Center, Non-controlled, Open-label, Observational Design

Trial Profile

Investigation of Pharmacokinetics, Safety, and Tolerability of a Single Oral 25 mg BAY 1142524 IR Tablet Dose in Male and Female Subjects With Renal Impairment and in Age-, Gender-, and Weight-matched Healthy Subjects in a Single Center, Non-controlled, Open-label, Observational Design

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Dec 2018

At a glance

  • Drugs Fulacimstat (Primary)
  • Indications Kidney disorders; Left ventricular dysfunction; Type 2 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors Bayer
  • Most Recent Events

    • 17 Dec 2018 Status changed from recruiting to active, no longer recruiting.
    • 16 Nov 2018 Planned End Date changed from 19 Dec 2018 to 11 Feb 2019.
    • 16 Nov 2018 Planned primary completion date changed from 19 Nov 2018 to 10 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top